Summary
Mereo Biopharma Group Plc (Mereo), formerly Mereo Biopharma Group Ltd is a specialty bio-pharmaceutical company which develops novel medicines for the treatment of rare and specialty diseases. The company’s pipeline products include BPS-804, which is used for the treatment of brittle bone syndrome; and BCT-197, an orally active p38 MAP kinase inhibitor developed for acute exacerbations of chronic obstructive pulmonary disease. Mereo also offers BGS-649, an orally active aromatase inhibitor developed for the treatment of obese men with hypogonadotrophic hypogonadism; and AZD-9668 , an oral neutrophil elastase inhibitor for the treatment of alpha-1 antitrypsin deficiency. The company collaborates with biotechnology and pharmaceutical companies. Mereo is headquartered in London, the UK

Mereo Biopharma Group Plc Key Recent Developments

Mar 31,2021: Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights
Dec 15,2020: Mereo biopharma provides update on AIM delisting and continued listing of its ADSs on Nasdaq, and provides update on agreements with Silicon Valley Bank and Kreos Capital
Nov 23,2020: Mereo BioPharma appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development
Oct 20,2020: Mereo BioPharma appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs

This comprehensive SWOT profile of Mereo Biopharma Group Plc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Mereo Biopharma Group Plc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.